Ricinoleic acid

Ricinoleic Acid: A Comprehensive Reference

1. Identity

Chemical Names and Structure

Ricinoleic acid, formally called 12-hydroxy-9-cis-octadecenoic acid, is a fatty acid classified as an unsaturated omega-9 fatty acid and a hydroxy acid. Its molecular formula is C₁₈H₃₄O₃; structurally it is cis-12-hydroxyoctadeca-9-enoic acid — an 18-carbon hydroxylated fatty acid bearing one double bond. Its IUPAC name is (9Z,12R)-12-hydroxyoctadec-9-enoic acid, and its CAS registry number is 141-22-0. Synonyms include 12-hydroxyoleic acid and, for its trans-isomer, ricinelaidic acid.

Ricinoleic acid has a unique molecular structure attributable to the hydroxyl group located in the middle of the unsaturated chain. In the triglycerol form, hydrogen bonding occurs with the hydroxyl groups, resulting in greater viscosity than in other oils. The hydroxyl group — only separated from the double bond by a methylene group — imparts increased oxidative stability, thereby providing castor oil a longer shelf life. Unlike most fatty acids, ricinoleic acid is soluble in more polar solvents such as alcohols.

Botanical Source

Ricinoleic acid is a major component of the seed oil obtained from the seeds of the castor plant (Ricinus communis L., Euphorbiaceae), the plant that also produces ricin. It is also found in the sclerotium of ergot (Claviceps purpurea Tul., Clavicipitaceae).

Castor oil is known to consist of up to 90% ricinoleic acid, 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids. With such a high percentage of ricinoleic acid, castor oil is essentially a technical-grade single-compound product — something that rarely happens in nature with plant oils. India is by far the largest producer of castor oil, followed by China, Brazil, Thailand, Ethiopia, and Paraguay.

Castor beans, the source of castor oil, contain allergenic (2S albumin) proteins as well as ricin; however, processed or refined castor oil is free from any of these substances and can be safely used in pharmaceutical applications.

Common Forms and Preparations

Ricinoleic acid is manufactured for industry by saponification or fractional distillation of hydrolyzed castor oil. In commerce and research, it appears in several distinct forms:

• Cold-pressed (virgin) castor oil: Yellow castor oil is unaltered and cold-pressed from the seeds of raw castor beans.
• Hydrogenated castor oil (castor wax): The most preferred modified form is hydrogenated castor oil, whose principal constituent is the glyceride of 12-hydroxystearic acid, sometimes called "castorwax."
• Sodium ricinoleate: The sodium salt, described as a "soap," used in personal care formulations and studied for its intestinal pharmacology.
• Zinc ricinoleate: The zinc salt is used in personal care products such as deodorants.
• Polyglycerol polyricinoleate (PGPR): A polymer of glycerol with ricinoleic acid side chains, used as an emulsifier in chocolate.
• Ricinoleate esters: including ethyl, methyl, glycol, isopropyl, and cetyl ricinoleate, used in cosmetic formulations as skin-conditioning agents.

These ingredients are reported to function primarily as skin-conditioning agents, emulsion stabilizers, and surfactants in cosmetics, although other functions are described.

2. Traditional and Historical Use

Prehistoric Evidence

The castor plant has been known since time immemorial, and its use in the prehistoric era has been evidenced by archaeological findings from Border Cave in South Africa. Traces of wax containing ricinoleic and ricinelaidic acids were found on a thin wooden stick, suggested to be a poison applicator, dating back to approximately 24,000 years ago. The identification of ricinoleic acid at the Border Cave site lends credence to the 2012 interpretation of this compound's presence on a 24,000-year-old wooden applicator. The precise nature of the application — whether as a toxin, adhesive, or another substance — has been subject to scholarly debate, with some researchers noting that ricinoleic acid and ricinelaidic acid are not themselves poisonous.

Ancient Egypt

The castor seeds and other parts of the castor plant were certainly utilized in ancient Egypt for pharmacological purposes. The castor plant has been known since time immemorial in the traditional medicine pharmacopeias of Mediterranean and eastern ancient cultures. It is still used in folk medicine worldwide. Castor bean has been mainly recommended as an anti-inflammatory, anthelmintic, anti-bacterial, laxative, abortifacient agent, and for wounds and ulcers, among many other indications.

The earliest findings of castor oil were discovered in ancient Egyptian tombs dating back to 4,000 B.C., and the first evidence of castor oil cultivation took place around 500 B.C. throughout central Egypt. There are multiple mentions of castor oil in the Ebers Papyrus, written around 1550 B.C., one of the world's oldest known medical documents offering hundreds of folk remedies and herbal medicinal formulas.

Traditional Chinese Medicine and Ayurveda

Castor oil has been prevalent throughout the history of Traditional Chinese Medicine and Ayurvedic medicine for its versatile array of applications. In Chinese traditional medicine, castor seeds were recommended for their anthelmintic activity; seed poultice and leaf juice were prescribed for external use to treat ulcers and chronic wounds, whereas latex was instilled in the ear for rhinitis treatment.

In Ayurvedic medicine, castor oil (known as eraṇḍa in Sanskrit) is considered to be balancing to both the vāta and kapha doshas. It is considered hot and penetrating in potency (uṣṇa and tīkṣṇa). It also belongs to the rejuvenative, anti-aging class of herbs known as rasāyana. In Ayurveda, castor oil preparations were used orally as laxative decoctions, applied topically to the skin and scalp, and given as medicated enemas (basti).

Africa

Castor oil has been found in ancient Egyptian tombs dating back to 4,000 B.C. and is native to the Ethiopian region of tropical East Africa. Evidence of its cultivation was discovered circa 500 B.C. in central Egypt where it was used in cosmetics, medicines, and as a lamp oil. Castor oil was used in other areas of ancient and medieval Africa to cure leather, in skin and hair preparations, and as a medicinal agent. In Sudan, Tanzania, and Kenya, it was held in higher regard than the popular sesame oil and was valued above olive oil.

Labor Induction

The oil obtained from the seeds of the castor oil plant Ricinus communis is one of the oldest drugs known to man. Castor oil is known primarily as an effective laxative; however, it was also used in ancient times with pregnant women to induce labor. Castor oil was the first reported medical procedure used to induce labor in the first half of the last century and was already used by the ancient Egyptians.

3. Key Constituents and Active Compounds

Ricinoleic Acid as the Principal Bioactive

Ricinoleic acid is the main active component of castor oil. The most studied pharmacological property of ricinoleic acid is its secretory action that occurs in the small intestine and colon of many mammals, including humans.

Castor oil is hydrolyzed in the small intestine by pancreatic enzymes, leading to the release of glycerol and ricinoleic acid, although 3,6-epoxyoctanedioic acid, 3,6-epoxydecanedioic acid, and 3,6-epoxydodecanedioic acid also appear to be metabolites.

EP3 Prostanoid Receptor Activation

The landmark 2012 study published in the Proceedings of the National Academy of Sciences by Tunaru et al. definitively established the molecular mechanism of ricinoleic acid's primary pharmacological actions. The effects of castor oil are mediated by ricinoleic acid, a hydroxylated fatty acid released from castor oil by intestinal lipases. Despite the widespread use of castor oil in conventional and folk medicine, the molecular mechanism by which ricinoleic acid acts was previously unknown. Tunaru et al. showed that the EP3 prostanoid receptor is specifically activated by ricinoleic acid and that it mediates the pharmacological effects of castor oil. In mice lacking EP3 receptors, the laxative effect and the uterus contraction induced via ricinoleic acid are absent.

Although a conditional deletion of the EP3 receptor gene in intestinal epithelial cells did not affect castor oil-induced diarrhea, mice lacking EP3 receptors only in smooth-muscle cells were unresponsive to this drug. Thus, the castor oil metabolite ricinoleic acid activates intestinal and uterine smooth-muscle cells via EP3 prostanoid receptors.

Using a large library of molecules that block cellular receptors, Tunaru et al. were able to identify two receptors that ricinoleic acid connects to: EP₃ and EP₄. Both are prostaglandin receptors, which have varied roles in the body, from changing the structure of neurons to controlling how blood clots.

Intestinal Secretory and Motility Mechanisms

Ricinoleic acid is the active metabolite released when intestinal enzymes break down castor oil. Ricinoleic acid acts as a surfactant, reduces absorption of fluid and electrolytes, and stimulates peristalsis — a series of intestinal muscle contractions that make bowel contents move.

The mechanistic basis for purgative actions likely includes the membrane-disruptive effects of detergent-like molecules such as sodium ricinoleate (a "soap"). These effects have been shown to be dose-related and to exhibit a threshold below which no laxative response was evident, in both animals and humans.

Capsaicin-Like Activity and Neurogenic Inflammation

Observational studies indicate that topical application of ricinoleic acid, the main component of castor oil, exerts remarkable analgesic and anti-inflammatory effects. Pharmacological characterization has shown similarities between the effects of ricinoleic acid and those of capsaicin, suggesting a potential interaction on sensory neuropeptide-mediated neurogenic inflammation.

Ricinoleic acid has been proven to produce relevant antinociceptive activities, probably through the desensitization of capsaicin-sensitive nerves, but — at variance with capsaicin — it is devoid of acute pungent and hyperalgesic properties. In conclusion, ricinoleic acid appears to be a new antinociceptive agent lacking the pungent and acute hyperalgesic properties of capsaicin.

Prostaglandin D2 Synthase Inhibition

In a preclinical experimental investigation, researchers found that ricinoleic acid (the active ingredient of castor oil) binds and inhibits the prostaglandin D2 synthase (PTGDS) enzyme responsible for producing PGD2, and thus may be a therapeutic option for hair loss.

Transdermal Penetration Enhancement

Castor oil and ricinoleic acid can enhance the transdermal penetration of other chemicals. This property underpins their use as delivery vehicles in pharmaceutical and cosmetic formulations.

4. Scientific Evidence by Area of Use

4.1 Laxative and Gastrointestinal Effects

Evidence strength: Strong (human data, FDA-approved use).

Castor oil is classified by the Food and Drug Administration (FDA) as generally recognized as safe and effective for use as a stimulant laxative. Although castor oil is primarily known for its laxative properties, the U.S. FDA has only approved the use of castor oil as a stimulative laxative. However, although castor oil is not recommended as a first-line treatment for constipation according to current medical guidelines, it continues to be utilized in traditional practices.

Loose bowel movements usually occur within 2–3 hours (range: 2–6 hours) following oral administration. The mechanism is well-characterized at the molecular level: the possible mechanism for labor induction and laxation following oral ingestion of castor oil is that ricinoleic acid is released by lipases in the intestinal lumen, and considerable amounts of ricinoleic acid are absorbed in the intestine, producing a strong laxative effect. Ricinoleic acid affects intestinal smooth muscle and thus alters intestinal ion transport and water flux. Based on cellular signaling studies and siRNA screening, prostaglandin E2 receptors have been identified as the target of ricinoleic acid, and the EP3 receptor mediates the effects of castor oil on the motility of the uterus and the intestine. Studies in mice with constitutive and conditional EP3 or EP4 receptor deficiency showed that the pharmacological effects of castor oil are mediated by activation of EP3 receptors on smooth-muscle cells.

The Joint FAO/WHO Expert Committee on Food Additives established an acceptable daily castor oil intake (for humans) of 0 to 0.7 mg/kg body weight.

4.2 Labor Induction (Obstetrics)

Evidence strength: Moderate; mixed results across study designs; not FDA-approved for this indication; large-scale RCTs lacking.

Castor oil has been used for centuries to induce labor, although clinical evidence remains limited. Early references to its use date back more than 400 years, with anecdotal reports even tracing its origins to ancient Egypt. In the 1960s, oxytocin replaced castor oil in obstetric care primarily to mitigate gastrointestinal side effects.

A 2022 systematic review and meta-analysis (PMC) examined this question directly. A total of 12 studies consisting of 1,653 pregnant women were included. The mean age of women who used castor oil was 24.72 years and in the control group was 24.67 years. Results showed that labor induction was significantly higher in the castor oil group than the control group (RR: 3.27; 95% CI [1.96, 5.46]).

A large 2026 retrospective cohort study at a university hospital included 1,015 women. A total of 1,015 women were included; 824 (82.1%) received castor oil and 191 (18.8%) underwent standard induction. The mean induction-to-delivery interval was 26.9 hours in the castor oil group versus 19.0 hours in the standard group. Additional induction was required in 50.5% of the castor oil group compared to 37.2% of the standard group. No significant differences were observed between groups regarding delivery mode or maternal/fetal complications. Castor oil appears to be a safe but slightly less effective option for inducing labor close to the calculated due date.

A prospective, randomized, double-blind, placebo-controlled clinical trial demonstrated the safety and efficacy of castor oil for induction of labor in multiparous post-date women, with similar perinatal outcomes and adverse effects between groups. However, this effect was not observed in primiparous women. One study demonstrated a significant interaction between castor oil and parity, with a higher rate of cesarean sections in primiparous women receiving castor oil cocktail. Consequently, castor oil cocktail is exclusively offered to multiparous women in some hospitals.

Overall, castor oil appears to be a safe but slightly less effective option for inducing labor close to the calculated due date, even in a high-risk population. Large-scale prospective randomized trials are warranted to further evaluate its role in clinical practice.

4.3 Anti-Inflammatory and Analgesic Effects

Evidence strength: Preclinical (animal/in vitro); limited direct human clinical trials on isolated ricinoleic acid.

Observational studies indicate that topical application of ricinoleic acid, the main component of castor oil, exerts remarkable analgesic and anti-inflammatory effects. Pharmacological characterization has shown similarities between the effects of ricinoleic acid and those of capsaicin, suggesting a potential interaction on sensory neuropeptide-mediated neurogenic inflammation. The aim of published studies was to assess ricinoleic acid's anti-inflammatory activities in comparison with capsaicin in several models of acute and subchronic inflammation. Acute inflammation was induced by intradermal injection of carrageenan in mice or by histamine in guinea-pig eyelid, and in each experiment the extent of the oedema thickness was measured.

It was found that the acute topical application of ricinoleic acid (0.9 mg/mouse) or capsaicin (0.09 mg/mouse) significantly increased mouse paw oedema induced by carrageenan, while an 8-day repeated topical treatment with the same doses of both compounds resulted in marked inhibition. On the basis of these results, ricinoleic acid may be seen as a new capsaicin-like, non-pungent anti-inflammatory agent suitable for peripheral application.

These findings are derived from animal experiments. Direct human clinical trials evaluating isolated ricinoleic acid for pain and inflammation as a primary endpoint remain limited in the published literature.

4.4 Wound Healing

Evidence strength: Preliminary; primarily in vitro and formulation research; human trial data sparse for isolated ricinoleic acid.

Ricinoleic acid has potential to promote wound healing because of its analgesic and anti-inflammatory properties. The analgesic and anti-inflammatory properties of natural products such as ricinoleic acid and capsaicin make them attractive for wound healing applications. However, capsaicin-based formulations present several drawbacks including pungent odor, skin irritation, and hyperalgesic pain, making them less attractive for wound healing applications. Ricinoleic acid extracted from castor oil may provide an alternative to capsaicin, if formulations can avoid oxidative rancidity and provide efficient permeation through the skin.

Research has focused on developing novel delivery systems. One study investigated the synthesis and characterization of ricinoleic acid liposomes infused in a hydrogel for topical application. Lecithin liposomes containing ricinoleic acid were prepared and incorporated into a chitosan solution and subsequently cross-linked with dialdehyde β-cyclodextrin (Di-β-CD). These formulation studies remain preclinical and do not constitute human efficacy data.

4.5 Dermatology: Skin and Hair

Evidence strength: Weak to moderate for specific dermatological claims; stronger safety evidence than efficacy evidence from human trials.

A 2025 narrative review published in Cureus — searching PubMed, Google Scholar, MEDLINE, and the Cochrane Library for articles up to April 20, 2025 — summarized current dermatological applications. Castor oil is an easily accessible vegetable oil, with many studies showing its usefulness for various dermatologic conditions. These include hair loss and quality, hyperpigmentation, acne, wound healing, anti-aging, and psoriasis. Castor oil has also been used for skin cleansing, onychomycosis, and increasing the penetration of active ingredients in topical formulations.

For androgenic alopecia specifically, the mechanism has been partially elucidated: recent studies have shown that prostaglandin D2 (PGD2) naturally inhibits hair growth and is found in higher concentrations on the scalp of those suffering from androgenic alopecia. In a preclinical experimental investigation, researchers found that ricinoleic acid (the active ingredient of castor oil) binds and inhibits the prostaglandin D2 synthase (PTGDS) enzyme responsible for producing PGD2, and thus may be a therapeutic option for hair loss. Evidence supports its use in hair care for improving luster and possibly combating androgenic alopecia via inhibition of prostaglandin D2 synthesis. These findings are, however, primarily preclinical.

Ricinoleic acid, the major constituent in castor oil along with its many derivatives, exerts skin-smoothing and moisturizing activities and may recover rough skin and acne.

Although topical application of oils may lead to limited systemic absorption of small volatile constituents, evidence indicates that the majority of lipid components remain localized within the stratum corneum, with minimal penetration into systemic circulation.

5. Body Systems and Health Areas

• Gastrointestinal system: Castor oil is primarily known for its laxative properties. Ricinoleic acid, once released in the gut, stimulates intestinal smooth-muscle contraction via EP3 receptor activation, increases luminal fluid secretion, and reduces fluid and electrolyte absorption.
• Reproductive system (uterus): The castor oil metabolite ricinoleic acid activates uterine smooth-muscle cells via EP3 prostanoid receptors.
• Nervous system / pain pathways: Ricinoleic acid has been proven to produce relevant antinociceptive activities, probably through the desensitization of capsaicin-sensitive nerves.
• Skin and integumentary system: Acts as an emollient, skin-conditioning agent, and possible anti-acne and anti-hyperpigmentation agent; being studied in wound healing formulations.
• Hair follicle biology: Preclinical evidence implicates ricinoleic acid in inhibiting prostaglandin D2 synthesis, potentially relevant to androgenic alopecia.
• Immune / inflammatory system: Preclinical studies suggest anti-inflammatory activity via modulation of neuropeptide release (substance P) and capsaicin-receptor desensitization.

6. Dosage Forms and Reported Dosages

Oral (Laxative)

A usual therapeutic adult dose of castor oil for laxative effect is 15 to 60 mL administered orally. About 90% of the fatty acid content in castor oil is the triglyceride formed from ricinoleic acid, which is the active component and acts as a laxative by stimulating secretion of fluid and electrolytes in the small intestines. One or two copious semi-fluid stools are released within 2 to 6 hours of administration.

Oral (Labor Induction — Reported in Studies)

One registered randomized controlled trial used a dose of 30 mL of castor oil (compared to 30 mL of water as control) in women at gestational ages between 41 weeks 0 days and 41 weeks 2 days. Other studies in the systematic review literature have used 60 mL as a single oral dose.

Acceptable Daily Intake (FAO/WHO)

The Joint FAO/WHO Expert Committee on Food Additives established an acceptable daily castor oil intake (for humans) of 0 to 0.7 mg/kg body weight. As ricinoleic acid constitutes approximately 90% of castor oil, applying this calculation to the 3,000 mg/day estimated acceptable daily intake in humans for castor oil (given the rapid hydrolysis of castor oil glyceride in the gastrointestinal tract), the acceptable daily intake of ricinoleic acid may be as high as 2,400 mg/person.

Topical

Ricinoleic acid and castor oil are applied topically in cosmetic and dermatological preparations at widely varying concentrations. Ricinoleic acid has been reported to be used at a maximum of 77.8% in moisturizing products as of 2023. Ricinoleic acid and sodium ricinoleate did not have separately reported concentrations of use in the Cosmetic Ingredient Review.

7. Safety Considerations and Interactions

Regulatory Safety Status

The Expert Panel for Cosmetic Ingredient Safety reviewed relevant animal and human data. The Panel concluded that ricinoleic acid, along with Ricinus communis (castor) seed oil and several ricinoleate derivatives, are safe as cosmetic ingredients in the practices of use and concentrations described in the safety assessment.

With more scientific literature on its mechanism of action, adverse effect profile, and toxicity, castor oil is now considered safe and effective according to FDA standards.

Gastrointestinal Adverse Effects

Known adverse effects include abdominal discomfort, nausea, cramps, griping, and/or faintness. Even at therapeutic doses, excessive irritation of the colon and violent purgation can occur. Diarrhea, GI irritation, and fluid and electrolyte depletion have been reported. It may rarely cause pelvic congestion.

Castor oil was not toxic in subchronic feeding studies in rodents at doses ranging up to 10–20% of the diet.

Reproductive Toxicology

No dose-related reproductive toxicity was found in mice fed up to 10% castor oil for 13 weeks. Female rats injected intramuscularly with castor oil on the first day after estrus had suppressed ovarian folliculogenesis and anti-implantation and abortive effects. Castor oil used as a vehicle control in rats receiving subcutaneous injections had no effect on spermatogenesis.

Because ricinoleic acid activates uterine smooth-muscle EP3 receptors and can induce uterine contraction, use of oral castor oil in pregnancy before term is a significant concern.

Carcinogenicity

Ricinoleic acid produced no neoplasms or hyperplasia in one mouse study and was not a tumor promoter in another mouse study, but did produce epidermal hyperplasia. Castor oil extract had a strong suppressive effect on S180 body tumors and ARS ascites cancer in male Kunming mice. These data are preclinical and require cautious interpretation.

Drug Interactions

By increasing intestinal motility, castor oil can potentially decrease transit time of concomitantly administered oral drugs and thereby decrease their absorption. Castor oil is a potent laxative, so the absorption of other oral drugs may be severely affected.

Castor oil and ricinoleic acid can enhance the transdermal penetration of other chemicals. This is relevant in topical formulations: inclusion of ricinoleic acid may increase the skin penetration of co-applied active substances.

Allergic Contact Dermatitis

Cosmetic Ingredient Review (CIR) expert panel assessments have concluded that PEG-castor oil derivatives are safe for use in cosmetic formulations at current concentrations, with a low incidence of skin sensitization and irritation reported in human and animal studies. Adverse reactions are rare, typically mild, and most strongly associated with native castor oil and ricinoleic acid, underscoring the importance of formulation-specific considerations in dermatologic practice.

Among lip care cosmetic products, the most common ingredients causing allergic contact dermatitis in a systematic review were castor oil, benzophenone-3, gallate, wax, and colophony. Case reports have documented contact cheilitis attributable to ricinoleic acid in lipsticks.

Lactation

It is not known whether castor oil or ricinoleic acid is distributed into breast milk.

Pediatric Use

Stimulant laxatives are generally avoided in children younger than 6–10 years of age for occasional constipation, although they are used in all age groups for colonic evacuation.

References

• Castor Oil: Properties, Uses, and Optimization of Processing Parameters in Commercial Production — PMC (PubMed Central)
• Ricinoleic acid — Wikipedia
• Toxicology and pharmacology of sodium ricinoleate — PubMed
• Antinociceptive activity of ricinoleic acid, a capsaicin-like compound devoid of pungent properties — European Journal of Pharmacology (ScienceDirect)
• Effect of ricinoleic acid in acute and subchronic experimental models of inflammation — PubMed
• Effect of ricinoleic acid in acute and subchronic experimental models of inflammation — PMC
• Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors — PNAS (Tunaru et al., 2012)
• Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors — PMC
• Bioactive polymeric formulations for wound healing — PMC
• Use of Castor Oil in Dermatology: A Narrative Review — PMC (Cureus, 2025)
• Castor Oil for Induction of Labor: A Safe and Effective Method — PMC (Healthcare, 2026)
• Induction of Labor Using Castor Oil Cocktail — Analysis of Real-world Data — PMC
• Effect and Safety of Castor Oil on Labor Induction and Prevalence of Vaginal Delivery: A Systematic Review and Meta-Analysis — PMC
• Castor oil for induction of labor in post-date pregnancies: A randomized controlled trial — ScienceDirect
• Ricin: An Ancient Story for a Timeless Plant Toxin — PMC
• Early evidence of San material culture represented by organic artifacts from Border Cave, South Africa — PNAS (d'Errico et al., 2012)
• A 7,000-year-old multi-component arrow poison from Kruger Cave, South Africa — PMC
• Re-Review Summary of Ricinus Communis (Castor) Seed Oil and Ricinoleates as Used in Cosmetics — PubMed (CIR Expert Panel)
• Safety Assessment of Ricinus Communis (Castor) Seed Oil and Ricinoleates — Cosmetic Ingredient Review (CIR)
• Castor Oil — StatPearls (NCBI Bookshelf)
• Castor Oil Monograph for Professionals — Drugs.com
• Ricinoleic Acid — ScienceDirect Topics Overview
• Targeting EP3 receptor for laxative drug discovery: molecular docking and virtual screening of ricinoleic acid analogues — Research Square (2026)